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1  | INTRODUC TION













The	 greatest	 global	 NCD	 burden	 arises	 due	 to	 cardiovascular	
disease	 (CVD),	 responsible	 for	 17.9	million	 deaths	 (a	 third	 of	 total	
mortality),	and	45%	of	NCD‐induced	mortality	(Roth	et	al.,	2017).	In	
Europe,	CVD	 is	 responsible	 for	3.9	million	deaths	 (45%	of	deaths),	
and	whilst	CVD	mortality	rates	are	reducing,	the	absolute	numbers	
have	 increased	 in	 the	 last	 25	 years,	 due	 to	 an	 increasingly	 ageing	













is	 evidence	 for	 over	 50	 gene	 polymorphisms	 playing	 a	 role	 in	 the	








2016),	 yet	 all	 are	modifiable	 through	 improved	 lifestyles	 including	
reducing	 salt,	 saturated	 fat	and	 refined	carbohydrate	 intake,	exer‐
cising,	 increasing	 intake	 of	 antioxidant	micronutrients	 and	 regular	
moderate	alcohol	consumption	(Joseph	et	al.,	2017).
Periodontitis	 is	 also	 a	 NCD	 with	 a	 high	 prevalence	 of	 45%–
50%	 overall,	 with	 the	 most	 severe	 form	 affecting	 11.2%	 of	 the	




and	caries)	 contributed	 the	most	YLD	 in	age‐standardized	preva‐
lence	rates	from	354	diseases	and	injuries	across	195	countries	(G.	
B.	D.	Disease	Injury	&	Incidence	&	Prevalence	Collaborators,	2018).	




Material and Methods: There	 is	now	a	significant	body	of	evidence	 to	support	 in‐
dependent	associations	between	severe	periodontitis	and	several	NCDs,	in	particu‐
lar	CVD.	 In	2012	a	 joint	workshop	was	held	between	 the	European	Federation	of	












K E Y W O R D S
anti	thrombotic	therapy,	atherosclerosis,	bateremia,	cardiovascular	disease,	chronic	
inflammation,	periodontal	therapy,	periodontitis
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al.,	 2013),	 chronic	 obstructive	 pulmonary	 disease	 (Linden,	 Lyons,	
&	Scannapieco,	2013)	and	chronic	kidney	disease	 (CKD)	 (Sharma,	
Dietrich,	 Ferro,	Cockwell,	&	Chapple,	2016).	 Indeed,	 severe	peri‐
odontitis	 is	 independently	 and	 significantly	 associated	 with	 all‐
cause	and	cardiovascular	mortality	in	several	different	populations	
(Linden	 et	 al.,	 2012;	 Sharma	 et	 al.,	 2016).	 Proposed	mechanisms	












upon	 four	 technical	papers	 that	 systematically	 reviewed	 the	evi‐
dence	for	epidemiological	associations	between	periodontitis	and	
incident	CVD	 (Dietrich,	 Sharma,	Walter,	Weston,	&	Beck,	 2013),	
mechanisms	of	 biological	 plausibility	 relating	 to	periodontal	 bac‐
teria	and	systemic	inflammation	(Reyes,	Herrera,	Kozarov,	Roldan,	
&	Progulske‐Fox,	2013;	Schenkein	&	Loos,	2013)	and	periodontal	
intervention	 studies	 (D'Aiuto,	 Orlandi,	 &	 Gunsolley,	 2013).	 The	
workshop	concluded	that	there	was	consistent	and	strong	epide‐
miological	 evidence	 that	 periodontitis	 imparts	 increased	 risk	 for	






biological	 mechanisms,	 intervention	 trials	 were	 not	 sufficiently	
adequate	to	draw	further	conclusions	at	that	time.
The	present	workshop	was	jointly	organized	by	the	EFP	and	the	
World	 Heart	 Federation	 (WHF)	 to	 include	 global	 experts	 in	 both	
periodontal	 and	 cardiovascular	disciplines	 and	was	held	 in	Madrid	
on	18th	and	19th	February	2019.	Four	 technical	 reviews	updating	
the	 evidence	 base	 from	 the	 2012	 workshop	 were	 prepared	 and	
supplemented	by	additional	studies	discussed	at	the	workshop.	The	
reviews	focussed	on	epidemiological	associations	(Herrera,	Molina,	
Buhlin,	 &	 Klinge,	 2019),	 mechanistic	 links	 (Schenkein,	 Papapanou,	





evidence	published	 since	 the	2012	workshop,	 there	 are	biological	




Furthermore,	 section	 4.3	 “What is the effect of statin intake on 
clinical periodontal outcomes?”	and	section	5	“Cardiovascular risks and 






2  | EPIDEMIOLOGIC E VIDENCE ON THE 
A SSOCIATION BET WEEN PERIODONTITIS 
AND C VD
2.1 | Do people with periodontitis have a higher 
prevalence of subclinical cardiovascular disease?
There	 is	evidence	 from	epidemiological	 studies	 that	periodontitis	








2.2 | Do people with periodontitis have a higher 
prevalence of coronary artery disease and risk of 
myocardial infarction and other coronary events?
There	is	robust	evidence	from	epidemiological	studies	for	a	positive	












2.3 | Do people with periodontitis have a higher 











definitions.	 Furthermore,	 a	 recent	 analysis	 of	 data	 from	 the	ARIC	
study	 demonstrated	 an	 association	 between	 periodontal	 profile	
class	 and	 incident	 ischaemic	 stroke.	 In	 this	 cohort,	 patients	 with	






2.4 | Do people with periodontitis have a higher 
prevalence and incidence of Peripheral Artery 
Disease (PAD)?
There	 is	 limited	 but	 consistent	 evidence	 that	 individuals	 with	
periodontitis	have	a	higher	prevalence	and	incidence	of	PAD	com‐
pared	 to	 individuals	without	periodontitis	 (Yang	et	al.,	2018).	For	
cross‐sectional	 data,	 the	 most	 significant	 evidence	 comes	 from	
two	large,	population‐based	studies	in	the	United	States	(NHANES	
1999–2002)	and	South	Korea	(KoGES‐CAVAS).	Both	studies	found	




val	 [1.2;	2.4])	 and	2.0	 (95%	CI	 [1.1;	3.9]),	 respectively	 (Ahn	et	 al.,	
2016;	 Lu,	 Parker,	 &	 Eaton,	 2008).	One	 prospective	 cohort	 study	
conducted	 in	male	veterans	 in	the	United	States	reported	a	posi‐
tive	 association	 between	 periodontitis	 (measured	 by	 severity	 of	





2.5 | Do people with periodontitis have a higher risk of 
other CVDs or conditions (heart failure, atrial fibrillation)?






2.6 | Do people with a history of cardiovascular 




2.7 | Do people with periodontitis with history of 
cardiovascular disease have a higher chance of 
experiencing a subsequent event?




nificant	 association	 (HR	=	2.8,	95%	CI	 [1.2;	6.5])	with	 recurrent	
cerebrovascular	events	(Sen	et	al.,	2013).
3  | MECHANISMS THAT MAY E XPL AIN 
THE EPIDEMIOLOGIC AL A SSOCIATIONS 
BET WEEN PERIODONTITIS AND C VD
3.1 | Is there evidence of a higher incidence of 
bacteremia following oral function/intervention in 









health	 status	 in	a	 systematic	 review,	 suggesting	a	higher	 risk	of	
bacteremia	 associated	 with	 gingival	 inflammation	 (Tomas,	 Diz,	
Tobias,	Scully,	&	Donos,	2012).	A	recent	randomized	clinical	trial	
(RCT)	 concluded	 that	 periodontal	 therapy	 (by	 means	 of	 scaling	
and	root	planing,	SRP)	 induced	bacteremia	in	both	gingivitis	and	
periodontitis	 patients,	 but	 the	 magnitude	 and	 frequency	 were	
greater	among	periodontitis	patients	(Balejo	et	al.,	2017).
Whilst	 there	 are	methodological	 limitations	 in	 some	of	 the	 re‐
ported	 studies,	 the	 overall	 picture	 supports	 the	 contention	 that	
bacteremia	 results	 from	daily	 life	 activities	 and	oral	 interventions,	
and	it	is	more	frequent	of	longer	duration	and	involves	more	virulent	
bacteria	in	periodontitis	patients.
3.2 | Is there evidence for the presence of oral 
bacteria in atheroma lesions?
There	 is	 evidence	 through	 traces	 of	 DNA,	 RNA	 or	 antigens	 derived	
from	 oral	 bacterial	 species,	mainly	 periodontal	 pathogens,	 that	 have	
been	 identified	 in	 atherothrombotic	 tissues.	 Studies	 have	 attempted	




Kristoffersen,	 Abesha‐Belay,	 &	 Olsen,	 2014;	 Mahendra,	 Mahendra,	
Felix,	&	Romanos,	2013).	At	least	two	studies	have	demonstrated	viable	
P. gingivalis and A. actinomycetemcomitans	 in	 atherothrombotic	 tissue	
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when	culturing	the	atheroma	samples	(Kozarov,	Dorn,	Shelburne,	Dunn,	
&	Progulske‐Fox,	2005;	Rafferty	et	al.,	2011).
3.3 | Do we have evidence that periodontal 
bacteria and/or bacterial products and virulence 






and	 coronary	 lesions	 after	 bacteremia	 in	 normocholesterolaemic	
pigs	(Schenkein	&	Loos,	2013).
Recently,	 further	 evidence	 has	 emerged	 using	 hyperlipidemic	
ApoEnull	mice	after	infection	with	P. gingivalis	and	also	with	a	poly‐
microbial	 experimental	 infection	 (P. gingivalis, Treponema denticola, 
Tannerella forsythia and Fusobacterium nucleatum).	 A	 polymicrobial	
infection	 was	 shown	 to	 induce	 aortic	 toll‐like	 receptor	 (TLR)	 and	




tal	pathogens	(P. gingivalis, A. actinomycetemcomitans,	etc.)	(Reyes	et	
al.,	2013).	In vivo and in vitro	studies	demonstrate	the	importance	of	
the	fimbriae	of	P. gingivalis	to	host	cell	entry	and	to	promote	athero‐
thrombotic	lesions	in	experimental	models	(Yang	et	al.,	2014).	In vitro 




3.4 | Do we have evidence that periodontitis 
patients exhibit increased production and/or levels of 




CVD	and	periodontitis	 patients	 compared	with	 either	 condition	
alone.	The	effect	of	periodontal	 therapy	has	been	shown	to	as‐




in	 periodontitis	 patients	 and	 lower	 levels	 of	 IL‐4	 and	 IL‐18.	 The	
effect	 of	 periodontal	 therapy	has	 shown	a	 significant	 decrease	 in	
the	serum	levels	of	IL‐6,	serum	amyloid	A	and	alpha	1	anti‐chymo‐
trypsin.	Peripheral	 neutrophils	 from	periodontitis	 patients	 release	




3.5 | Do we have evidence that periodontitis 
patients develop elevations in thrombotic factors 
that are also associated with the pathophysiology of 
atherothrombosis?






levels	 of	 platelet	 activation	 markers	 in	 periodontitis	 patients	 and	





3.6 | Do we have evidence that periodontitis 
patients demonstrate elevated serum antibody levels 
that cross‐react with antigens in cardiovascular 
tissues?
There	 is	 evidence	 that	 HSPs	 from	 periodontal	 pathogens	
(Porphyromonas gingivalis,	Tannerella forsythia, Aggregatibacter actin‐
omycetemcomitans and Fusobacterium nucleatum)	generate	antibod‐











cular	 disease	 and	 cardiovascular	 disease).	 The	ATHEROREMO‐IVUS	
study	 failed	 to	demonstrate	an	association	between	serum	 levels	of	
IgG	and	IgA	against	P. gingivalis,	A. actinomycetemcomitans,	T. forsythia 
and P. intermedia	and	major	adverse	cardiac	events	(MACE)	(de	Boer	et	
al.,	2014).	This	is	consistent	with	data	from	Boillot	et	al.	(2016).
3.7 | Do we have evidence that periodontitis 
patients exhibit dyslipidaemia?
There	is	evidence	from	systematic	reviews	that	serum	total	choles‐
terol	 levels,	 low‐density	 lipoproteins	 (LDL),	 triglycerides,	very‐low‐
density	lipoproteins	(VLDL),	oxidized	LDL	and	phospholipase	A2	are	
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3.8 | Do we have evidence for peripheral blood 
neutrophil hyper‐responsiveness in reactive oxygen 







Chapple,	 2007a).	 This	 hyper‐reactivity	 to	 stimulation	 by	 periodon‐
tal	 bacteria	 is	 reduced	 following	 successful	 periodontal	 therapy	 to	
control	 patient	 levels,	 but	 the	 unstimulated	 hyperactivity	 remains,	
suggesting	that	constitutive	and	reactive	mechanisms	underlie	neu‐
trophil	 hyper‐responsiveness	 in	 periodontitis	 (Matthews,	 Wright,	
Roberts,	 Ling‐Mountford,	 et	 al.,	 2007b).	 Gene	 expression	 data	 in	
PBNs	support	the	functional	data	(Wright,	Matthews,	Chapple,	Ling‐
Mountford,	&	Cooper,	2008).	Serum	antioxidant	levels	and	those	in	
gingival	 crevicular	 fluid	 (GCF)	are	 reduced	 in	periodontitis	patients,	




myeloperoxidase	 (MPO),	 cell‐free	 DNA	 and	 DNA‐MPO	 complexes	
(Range	et	al.,	2014).
3.9 | Are there common genetic risk factors 
between periodontitis and CVDs?
There	 is	 scientific	 evidence	 of	 pleiotropy	 between	 periodontitis	
and	cardiovascular	diseases	(Aarabi	et	al.,	2017;	Munz	et	al.,	2018;	
Schaefer	 et	 al.,	 2015,	 2011).	 The	 highly	 pleiotropic	 genetic	 locus	
CDKN2B‐AS1	 (chromosome	 9,	 p21.3)	 associated	with	 coronary	 ar‐
tery	disease,	type	2	diabetes,	ischaemic	stroke	and	Alzheimer’s	dis‐
ease	is	also	consistently	associated	with	periodontitis	(Aarabi	et	al.,	
2017;	 Ernst	 et	 al.,	 2010;	 Loos,	 Papantonopoulos,	 Jepsen,	&	 Laine,	
2015;	Munz	et	al.,	2018).	 Its	function	appears	to	be	related	to	the	
regulation	of	gene	expression	(Hubberten	et	al.,	2019).	Interestingly,	
a	 pilot	 study	 identified	 that	 a	 genetic	 variant	 in	 the	CDKN2B‐AS1 
locus	was	associated	with	the	extent	of	elevated	levels	of	C‐reactive	
protein	in	periodontitis	(Teeuw,	Laine,	Bizzarro,	&	Loos,	2015).
A	 conserved	 non‐coding	 element	within	CAMTA1	 upstream	of	
VAMP3,	also	first	identified	as	a	genetic	susceptibility	locus	for	cor‐
onary	artery	disease,	was	found	to	be	associated	with	periodontitis	









These	shared	genetic	 factors	suggest	a	mechanistic	 link	or	 im‐





loci CDKN2B‐AS1 (ANRIL), PLG, CAMTA1/VAMP3 and VAMP8 could 
partially	explain	the	epidemiological	link	between	periodontitis	and	
cardiovascular	diseases.
4  | E VIDENCE FROM INTERVENTION 
STUDIES
4.1 | Is there an effect of periodontitis treatment in 
preventing or delaying ACVD events?
4.1.1 | Primary prevention
There	 have	 been	 no	 prospective	 randomized	 controlled	
periodontal	 intervention	 studies	 on	 primary	 prevention	 of	
cardiovascular	diseases	(including	first	ischaemic	events	or	car‐
diovascular	 death)	 since	 the	 last	 consensus	 report	 (Tonetti	 et	
al.,	2013).	The	Group	questioned	 the	 feasibility	of	performing	
adequately	 powered	 RCTs	 in	 primary	 prevention	 at	 a	 popula‐




habits	 (toothbrushing)	 (two	 studies	 (de	 Oliveira,	 Watt,	 &	 Hamer,	
2010;	Park	et	al.,	2019)),	dental	prophylaxis	(one	study	Lee,	Hu,	Chou,	
&	Chu,	2015),	 increased	self‐reported	dental	visits	(one	study	(Sen	





were	 linked	 to	 a	 database	 of	 hospital	 admissions	 and	deaths	with	
follow‐up	 until	 December	 2007	 (Information	 Services	 Division,	
Edinburgh)	(de	Oliveira	et	al.,	2010).	Participants	who	brushed	less	







the	 incidence	 rate	of	ACVD	events	 from	2000	 to	2015	 (Lee	 et	 al.,	
2015).	The	hazard	ratio	for	acute	myocardial	infarction	was	reduced	
more	in	the	group	of	periodontitis	patients	who	received	dental	pro‐
phylaxis	 (HR	 =	 0.90,	 95%	CI	 [0.86;	 0.95])	 than	 intensive	 treatment	
(including	 gingival	 curettage,	 scaling	 and	 root	 planing,	 and/or	 peri‐
odontal	 flap	operation	and/or	 tooth	extraction)	 (HR	=	1.09,	95%	CI	
[1.03;	1.15]).	Consistent	reductions	in	the	incidence	rate	of	ischaemic	
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stroke	were	observed	in	both	the	dental	prophylaxis	(HR	=	0.78,	95%	
CI	 [0.75;	0.91])	 and	 intensive	 treatment	 groups	 (HR	=	0.95,	95%	CI	
[0.91;	0.99]).
A	 cohort	 of	 8,999	 patients	 with	 periodontitis	 who	 received	 a	




cidence	 rate	–IR	=	1.28,	95%	CI	 [1.07;	1.53])	 compared	with	good	
responders,	suggesting	that	successful	periodontal	treatment	could	
reduce	the	incidence	of	ACVD	events.
In	the	Atherosclerosis	Risk	 in	Communities	 (ARIC)	study	 includ‐
ing	6,736	participants	followed	during	15	years,	self‐reported	regular	
dental	care	users	had	a	 lower	 risk	 for	 ischaemic	stroke	 (HR	=	0.77,	
95%	CI	 [0.63;	0.94])	 compared	with	episodic	 care	users	 (Sen	et	 al.,	
2018).



























4.2 | What is the effect of the treatment of 
periodontitis in improving surrogate parameters of 
CVD?
Table	 1	 summarizes	 the	 evidence	 on	 the	 effect	 of	 periodontal	
therapy	 on	 surrogate	 markers	 of	 CVD.	 There	 is	 moderate	 evi‐
dence	 for	 reduction	 of	 low‐grade	 inflammation	 as	 assessed	 by	
serum	 levels	of	CRP,	 IL‐6	and	 improvements	 in	surrogate	meas‐
ures	of	endothelial	function	(flow‐mediated	dilatation	of	the	bra‐
chial	artery).




intima‐media	 thickness)	 and	 insufficient	 evidence	 of	 an	 effect	 on	
ACVD	biomarkers	of	coagulation,	endothelial	cell	activation	and	ox‐
idative	stress.
4.3 | What is the effect of statin intake on clinical 
periodontal outcomes?












2003;	 Poston	 et	 al.,	 2016)	 and	 possess	 anti‐microbial	 properties	
(Ting,	Whitaker,	&	Albandar,	2016).
































therapy	 (Fajardo,	Rocha,	 Sanchez‐Marin,	&	Espinosa‐Chavez,	 2010;	
Fentoglu	 et	 al.,	 2012;	 Sangwan,	 Tewari,	 Singh,	 Sharma,	 &	 Narula,	
2016).	In	a	randomized	placebo‐controlled	pilot	study	in	38	patients	












5  | C ARDIOVA SCUL AR RISKS AND 
COMPLIC ATIONS OF PERIODONTAL 
THER APEUTIC INTERVENTIONS
5.1 | Is there an ischaemic cardiovascular risk for 
patients undergoing periodontal therapy?
Non‐surgical	treatment	of	periodontitis	involving	supra‐	and	subgingi‐
val	instrumentation	of	the	affected	dentition	(under	local	anaesthesia)	









the	 question	 of	 whether	 performing	 longer	 sessions	 of	 periodontal	
treatment	could	contribute	to	an	individuals’	inflammatory	burden/risk	
and	 increase	their	short‐term	risk	of	suffering	from	a	vascular	event.	
TA B L E  1  Summary	of	the	evidence	on	the	effect	of	periodontal	therapy	on	surrogate	markers	of	cardiovascular	diseases
Topic Outcome
Number of RCTs 



















































Common	cIMT 1	RCT Kapellas	et	al.	(2014) Yes Limited
Abbreviation: RCT,	randomized	clinical	trial;	SR,	systematic	review.
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There	 is	 consistent	 and	 strong	observational	 evidence	 that	 common	
acute	 infections/inflammatory	 responses	are	associated	at	a	popula‐













reported	 a	non‐significant	 increase	 in	 the	 incidence	of	myocardial	
infarction	within	the	first	24	weeks	following	“invasive dental treat‐













is	associated	with	an	 increased	 risk	of	 incident	acute	cardiovascu‐
lar	events	(IR	=	1.5,	95%	CI	[1.09;	2.06])	within	the	first	4	weeks	of	
treatment	recorded.
In	 summary,	 the	 Group	 concluded	 that	 delivering	 periodontal	
treatment	is	safe	with	regard	to	cardiovascular	risk.
5.1.2 | In patients with established CVD
There	is	limited	evidence	on	the	effects	of	“invasive dental treatment” 
on	 the	 incidence	 of	 ischaemic	 events	 in	 patients	with	 established	
CVD	or	after	an	event.
A	small	RCT	on	the	effects	of	the	treatment	of	periodontitis	on	
CVD	 biomarkers	 in	 patients	with	 established	CVD	 (Montenegro	
et	 al.,	 2019)	 showed	 no	 cardiovascular	 adverse	 events	 within	 3	
months	 of	 completion	 of	 scaling	 and	 root	 planing	 (periodontal	
therapy).
In	 the	PAVE	 feasibility	 randomized	 secondary	 prevention	 trial,	
provision	of	 periodontal	 scaling	 and	 root	 planing	 treatment	 in	 pa‐
tients	with	established	CVD	did	not	 increase	the	 incidence	of	car‐
diovascular	 events	 compared	 to	 the	 control	 group	 (community	
treatment)	within	6	months	(Beck	et	al.,	2008).
In	 summary,	 the	 Group	 concluded	 that	 delivering	 periodontal	
treatment	is	safe	with	regard	to	cardiovascular	risk	in	patients	with	
established	CVD.






Perioperative	 bleeding	 risk	 varies	 according	 to	 the	 extent	
and	 invasiveness	 of	 the	 periodontal	 procedure	 performed.	 The	
majority	 of	 periodontal	 procedures	 may	 be	 grouped	 within	 the	
ESC/AHA/EHRA	 (Steffel	et	al.,	2018a,	2018b).	Low	bleeding	 risk	
group	(frequency	less	than	1%	of	post‐operative	bleeding)	group:	
supragingival	 polishing,	 non‐surgical	 periodontal	 treatment,	 con‐




as	 block	 bone	 harvesting,	 sinus	 floor	 elevation	 and	 procedures	




5.2.1 | In patients undergoing antiplatelet therapy
Individuals	 undergoing	 single	 acetylsalicylic	 acid	 (ASA)	 therapy	











Thus,	 current	 evidence	 does	 not	 support	 discontinuation	 of	
antiplatelet	 therapy	before	dental	procedures,	 irrespective	of	 the	
type	of	therapy	employed	(single	or	dual	antiplatelet	therapy)	or	the	
type	 of	 procedure	 performed	 (single,	 multiple	 tooth	 extractions,	
non‐surgical	 and	 surgical	 periodontal	 therapy	 and	 dental	 implant	
procedures).
5.2.2 | In patients undergoing anticoagulant therapy
Vitamin K antagonists
In	patients	taking	oral	anticoagulant	therapy	(vitamin	K	antagonists,	
VKA)	 and	 undergoing	 dental	 extraction,	 minor	 dental	 procedures	
10  |     SANZ et Al.




continuing	 VKA	 and	 undergoing	 either	 minor	 dental	 surgery	 or	
other	higher‐risk	procedures	when	compared	to	non‐VKA	patients	




Limited	 trials	 and	 evidence	 are	 available	 on	 the	management	 of	
patients	on	novel	oral	anticoagulant	 (NOAC)	therapy	undergoing	
dental	treatment;	hence,	the	Group	concluded	that	further	stud‐





measures	 when	 comparing	 groups	 continuing	 NOAC	 and	 groups	
discontinuing	 NOAC	 therapy	 (Kwak	 et	 al.,	 2019;	 Lababidi	 et	 al.,	
2018;	 Patel	 et	 al.,	 2017;	 Yagyuu	 et	 al.,	 2017)	 and	with	 reported	
timing	of	discontinuation	and	 reinstitution	varying	greatly.	When	
comparing	 NOAC	 patients	 with	 healthy	 individuals,	 there	 seems	




6.1 | Recommendations for oral health professionals 








•	 Patients	 with	 periodontitis	 and	 a	 diagnosis	 of	 CVD	 should	 be	
informed	 that	 they	 may	 be	 at	 higher	 risk	 for	 subsequent	 CVD	
complications,	and	therefore,	they	should	regularly	adhere	to	the	



























•	 Hypertension.	 It	 is	 recommended	 to	 measure	 the	 patients’	




•	 Medication	 with	 antiplatelet	 and	 anticoagulant	 drugs.	 Since	
periodontal	 and	 implant	 surgical	 procedures	 usually	 impart	
only	 a	 low‐to‐medium	 risk	 of	 bleeding	 in	 general	 terms,	 the	
dentist	should	not	change	a	patient's	medication,	or	in	cases	
of	 doubt,	 he/she	 should	 consult	 the	 physician/cardiologist	








Various	 approaches	 for	 peri‐operative	 management	 of	 anti‐
coagulant	 therapy	 have	 been	 suggested.	 The	Group	 reviewed	 the	




ternationalized	normalized	 ratio)	 is	3.5	or	above,	 the	expert	group	
recommends	that	dental	clinicians	seek	advice	and	consult	with	the	
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medication	 should	be	discussed	 and	agreed	upon	with	 the	 respon‐










acid	mouthwashes,	 compressive	 gauze	 soaked	 in	 tranexamic	 acid)	
should	be	used	and	dental	clinicians	should	consider	the	confound‐
ing	effect	of	local	anaesthetic	with	vasoconstrictors.
•	 Patients	with	 a	 risk	of	 endocarditis	 should	be	premedicated	





People	 without	 a	 diagnosis	 of	 CVD,	 but	 with	 risk	 factors	 for	
CVD	 should	 be	 informed	 about	 their	 CVD	 risk	 and	 referred	 to	
a	 physician	 for	 appropriate	 risk	 assessment,	 diagnostic	 testing	
and	 follow‐up	 care.	 For	 oral	 health	 professionals,	 risk	 assess‐
ment	 may	 be	 performed	 based	 upon	 the	 recommendations	 of	
the	 European Society of Cardiology (Systematic COronary Risk 
Evaluation, SCORE)	 (Sixth	 Joint	 Task	 Force	 of	 the	 European	
Society	 of	 Cardiology	 &	 Other	 Societies	 on	 Cardiovascular	
Disease	 Prevention	 in	 Clinical	 Practice,	 2016).
6.2 | Recommendations for 
physicians and other medical health professions for 










physician	 should	 seek	 to	 ascertain	 that	 appropriate	periodontal	
care	and	maintenance	are	being	provided.














•	 The	 physician	 should	 liaise	 with	 the	 dental	 surgeon	 over	 peri‐
odontitis	 management	 in	 CVD	 patients	 on	 anticoagulant/anti‐
platelet	therapy	prior	to	the	oral	intervention	and/or	periodontal	
surgery,	to	avoid	excess	bleeding	or	the	risk	of	ischaemic	events.
6.3 | Recommendations for patients at the dental 
surgery/ office who have CVD or are found to be at 
risk of CVD
•	 People	with	CVD	must	 be	 aware	 that	 gum	disease	 is	 a	 chronic	
condition,	which	may	aggravate	their	CVD	and	requires	 lifelong	
attention	and	professional	care.
•	 There	 is	 a	 need	 to	 clean	 the	 teeth	 and	 gums	 very	 carefully	 at	
home.	 Personalized	 advice	 will	 be	 provided	 by	 the	 oral	 health	
professional.
This	may	include	the	following:




•	 Use	of	 specific	 dentifrices	 and/or	mouth	 rinses	with	proven	






















Patients	 should	 understand	 that	 it	 is	 important	 to	 keep	 their	
mouth	 and	whole	 body	 as	 healthy	 as	 possible	with	 regular	 dental	
and	medical	visits.
6.4 | Recommendations for patients with CVD 
at the physician's practice/office







6.4.2 | What should I look for that may tell me I 




















6.4.4 | What can I do to prevent gum disease?
You	need	 to	 clean	 your	 teeth	 and	 gums	 twice	daily	 at	 home	 for	
a	minimum	of	 2	min.	 Also,	 cleaning	 between	 your	 teeth	 daily	 is	
important	and	your	oral	health	professional	will	show	you	how	to	
do	this.	You	should	visit	a	dental	surgeon	as	soon	as	possible	for	





Mariano Sanz  https://orcid.org/0000‐0002‐6293‐5755 
Søren Jepsen  https://orcid.org/0000‐0002‐4160‐5837 
Filippo Graziani  https://orcid.org/0000‐0001‐8780‐7306 
David Herrera  https://orcid.org/0000‐0002‐5554‐2777 
Bruno Loos  https://orcid.org/0000‐0002‐8794‐552X 
Phoebus Madianos  https://orcid.org/0000‐0003‐0935‐5601 
Lior Shapira  https://orcid.org/0000‐0001‐9145‐5155 
Maurizio Tonetti  https://orcid.org/0000‐0002‐2743‐0137 
Israel	Gotsman	  https://orcid.org/0000‐0003‐0935‐5601  
R E FE R E N C E S
Aarabi,	 G.,	 Zeller,	 T.,	 Seedorf,	 H.,	 Reissmann,	 D.	 R.,	 Heydecke,	 G.,	
Schaefer,	 A.	 S.,	 &	 Seedorf,	 U.	 (2017).	 Genetic	 susceptibility	 con‐




S.,	&	Kim,	H.	D.	 (2016).	Periodontitis	 is	 associated	with	 the	 risk	of	
subclinical	atherosclerosis	and	peripheral	arterial	disease	in	Korean	













procedural	 rinse	on	bacteremia	 in	periodontal	patients:	A	 random‐
ized	clinical	trial.	Journal of Applied Oral Science,	25,	586–595.	https	://
doi.org/10.1590/1678‐7757‐2017‐0112
Beck,	 J.	 D.,	 Couper,	 D.	 J.,	 Falkner,	 K.	 L.,	 Graham,	 S.	 P.,	 Grossi,	 S.	
G.,	 Gunsolley,	 J.	 C.,	 …	 Genco,	 R.	 J.	 (2008).	 The	 Periodontitis	
and	 Vascular	 Events	 (PAVE)	 pilot	 study:	 Adverse	 events.	
Journal of Periodontology,	 79,	 90–96.	 https	://doi.org/10.1902/
jop.2008.070223
Belanger,	 M.,	 Kozarov,	 E.,	 Song,	 H.,	Whitlock,	 J.,	 &	 Progulske‐Fox,	 A.	
(2012).	 Both	 the	 unique	 and	 repeat	 regions	 of	 the	Porphyromonas 
     |  13SANZ et Al.
gingivalis	 hemagglutin	 A	 are	 involved	 in	 adhesion	 and	 invasion	 of	
















and Haemostasis,	 117,	 1432–1439.	 https	://doi.org/10.1160/
TH17‐01‐0040
Boillot,	A.,	Range,	H.,	Danchin,	N.,	Kotti,	S.,	Cosler,	G.,	Czernichow,	S.,	
…	 Simon,	 T.	 (2016).	 Periodontopathogens	 antibodies	 and	 major	
adverse	 events	 following	 an	 acute	 myocardial	 infarction:	 Results	
from	 the	 French	 Registry	 of	 Acute	 ST‐Elevation	 and	 Non‐ST‐
Elevation	Myocardial	 Infarction	 (FAST‐MI).	 Journal of Epidemiology 
and Community Health,	 70,	 1236–1241.	 https	://doi.org/10.1136/
jech‐2015‐207043
Caula,	A.	 L.,	 Lira‐Junior,	R.,	 Tinoco,	E.	M.,	&	Fischer,	R.	G.	 (2014).	The	
effect	 of	 periodontal	 therapy	on	 cardiovascular	 risk	markers:	A	6‐
month	randomized	clinical	trial.	Journal of Clinical Periodontology,	41,	
875–882.	https	://doi.org/10.1111/jcpe.12290	
Centers	 for	Disease	Control	 and	Prevention	 (2011).	Healthy aging at a 
glance 2011.	Atlanta,	GA:	Centers	for	Disease	Control	and	Prevention.
Centers	for	Disease	Control	and	Prevention	(2013)	The state of aging and 









tis:	Cause	or	effect?	Journal of Clinical Periodontology,	34,	103–110.	
https	://doi.org/10.1111/j.1600‐051X.2006.01029.x
Chapple,	 I.	 L.,	 Genco,	 R.,	 &	 Working	 Group	 2	 of	 the	 Joint	 EFP/AAP	
Workshop	(2013).	Diabetes	and	periodontal	diseases:	Consensus	re‐
port	of	the	Joint	EFP/AAP	Workshop	on	Periodontitis	and	Systemic	
Diseases.	Journal of Clinical Periodontology,	40(Suppl	14),	S106–112.	
https	://doi.org/10.1111/jcpe.12077	
Chen,	D.	Y.,	Lin,	C.	H.,	Chen,	Y.	M.,	&	Chen,	H.	H.	 (2016).	Risk	of	atrial	
fibrillation	 or	 flutter	 associated	 with	 periodontitis:	 A	 nationwide,	
population‐based	 cohort	 study.	 PLoS ONE,	 11,	 e0165601.	 https	://
doi.org/10.1371/journ	al.pone.0165601
Chen,	 T.	 T.,	 D'Aiuto,	 F.,	 Yeh,	 Y.	 C.,	 Lai,	M.	 S.,	 Chien,	 K.	 L.,	 &	 Tu,	 Y.	 K.	
(2019).	Risk	of	myocardial	infarction	and	ischemic	stroke	after	den‐







Couper,	 D.	 J.,	 Beck,	 J.	 D.,	 Falkner,	 K.	 L.,	 Graham,	 S.	 P.,	 Grossi,	 S.	 G.,	
Gunsolley,	J.	C.,	…	Genco,	R.	J.	(2008).	The	Periodontitis	and	Vascular	
Events	 (PAVE)	 pilot	 study:	 Recruitment,	 retention,	 and	 community	
care	 controls.	 Journal of Periodontology,	 79,	 80–89.	 https	://doi.
org/10.1902/jop.2008.070216
D'Aiuto,	 F.,	 Gkranias,	 N.,	 Bhowruth,	 D.,	 Khan,	 T.,	 Orlandi,	 M.,	 Suvan,	
J.…TASTE	Group	(2018).	Systemic	effects	of	periodontitis	treatment	
in	patients	with	type	2	diabetes:	A	12	month,	single‐centre,	investi‐
gator‐masked,	randomised	trial.	Lancet Diabetes and Endocrinology,	6,	
954–965.	https	://doi.org/10.1016/S2213‐8587(18)30038‐X
D'Aiuto,	 F.,	 Orlandi,	M.,	 &	Gunsolley,	 J.	 C.	 (2013).	 Evidence	 that	 peri‐
odontal	 treatment	 improves	 biomarkers	 and	 CVD	 outcomes.	
Journal of Clinical Periodontology,	40(Suppl	14),	S85–105.	https	://doi.
org/10.1111/jcpe.12061	
de	Boer,	S.	P.,	Cheng,	J.	M.,	Range,	H.,	Garcia‐Garcia,	H.	M.,	Heo,	J.	H.,	









Effect	 of	 non‐surgical	 periodontal	 therapy	 along	 with	 myo‐inosi‐











and	incident	atherosclerotic	cardiovascular	disease.	Journal of Clinical 
Periodontology,	40,	S70–84.	https	://doi.org/10.1111/jcpe.12062	
Divaris,	K.,	Monda,	K.	L.,	North,	K.	E.,	Olshan,	A.	F.,	Lange,	E.	M.,	Moss,	
K.,	 …	 Offenbacher,	 S.	 (2012).	 Genome‐wide	 association	 study	 of	




antiplatelet	 therapy	 after	 tooth	 extraction	 and	minor	 oral	 surgery.	
Journal of the American Dental Association,	149,	132–138.	https	://doi.
org/10.1016/j.adaj.2017.09.052
















Estanislau,	 I.	M.,	 Terceiro,	 I.	 R.,	 Lisboa,	M.	 R.,	 Teles	 Pde,	 B.,	 Carvalho	
Rde,	S.,	Martins,	R.	S.,	&	Moreira,	M.	M.	(2015).	Pleiotropic	effects	
of	 statins	 on	 the	 treatment	 of	 chronic	 periodontitis–a	 systematic	
review. British Journal of Clinical Pharmacology,	79,	877–885.	https	://
doi.org/10.1111/bcp.12564	
14  |     SANZ et Al.
Fajardo,	M.	E.,	Rocha,	M.	L.,	Sanchez‐Marin,	F.	J.,	&	Espinosa‐Chavez,	E.	J.	
(2010).	Effect	of	atorvastatin	on	chronic	periodontitis:	A	randomized	
pilot	study.	Journal of Clinical Periodontology,	37,	1016–1022.	https	://
doi.org/10.1111/j.1600‐051X.2010.01619.x
Fentoglu,	O.,	Kirzioglu,	F.	Y.,	Ozdem,	M.,	Kocak,	H.,	Sutcu,	R.,	&	Sert,	T.	
(2012).	 Proinflammatory	 cytokine	 levels	 in	 hyperlipidemic	 patients	




tal	 therapy	 on	 C‐reactive	 protein	 level:	 A	 systematic	 review	 and	
meta‐analysis.	 Journal of Applied Oral Science,	 20,	 1–8.	 https	://doi.
org/10.1590/S1678‐77572	01200	0100002
Fu,	Y.	W.,	Li,	X.	X.,	Xu,	H.	Z.,	Gong,	Y.	Q.,	&	Yang,	Y.	(2016).	Effects	of	peri‐




G.	 B.	 D.	 Disease	 Injury	 and	 Incidence	 and	 Prevalence	 Collaborators	





G.	 B.	 D.	 Risk	 Factors	 Collaborators	 (2016).	 Global,	 regional,	 and	 na‐
tional	 comparative	 risk	 assessment	 of	 79	 behavioural,	 environ‐
mental	 and	 occupational,	 and	 metabolic	 risks	 or	 clusters	 of	 risks,	
1990–2015:	A	systematic	analysis	for	the	Global	Burden	of	Disease	




Graziani,	 F.,	 Cei,	 S.,	 Orlandi,	M.,	 Gennai,	 S.,	 Gabriele,	M.,	 Filice,	 N.,	 …	
D'Aiuto,	F.	(2015).	Acute‐phase	response	following	full‐mouth	versus	
quadrant	 non‐surgical	 periodontal	 treatment:	 A	 randomized	 clini‐






Heart	 Association,	 American	 College	 of	 Cardiology,	 Society	 for	
Cardiovascular	 Angiography	 and	 Interventions,	 American	 College	
of	Surgeons,	and	American	Dental	Association,	with	representation	
from	 the	 American	 College	 of	 Physicians.	 Journal of the American 
Dental Association,	 138,	 652–655.	 https	://doi.org/10.14219/	jada.
archi	ve.2007.0237
Hada,	D.	 S.,	 Garg,	 S.,	 Ramteke,	G.	 B.,	 &	 Ratre,	M.	 S.	 (2015).	 Effect	 of	
non‐surgical	 periodontal	 treatment	 on	 clinical	 and	 biochemi‐
cal	 risk	 markers	 of	 cardiovascular	 disease:	 A	 randomized	 trial.	
Journal of Periodontology,	 86,	 1201–1211.	 https	://doi.org/10.1902/
jop.2015.150249
Herrera,	D.,	Molina,	A.,	Buhlin,	K.,	&	Klinge,	B.	 (2019)	Periodontal	dis‐
eases	 and	 association	 with	 atherosclerotic	 disease.	 Periodontology 
2000,	(in	press).
Holdt,	M.	H.,	&	Teupser,	D.	(2015).	Genetic	background	of	atherosclero‐
sis	and	its	risk	factors.	In	The ESC textbook of preventive cardiology	(pp.	
21–25).	Oxford,	UK:	Oxford	University	Press.
Holmlund,	A.,	Lampa,	E.,	&	Lind,	L.	 (2017).	Poor	response	to	periodon‐




P.,	…	Schaefer,	A.	S.	 (2019).	 Linear	 isoforms	of	 the	 long	noncoding	
RNA	 CDKN2B‐AS1	 regulate	 the	 c‐myc‐enhancer	 binding	 factor	




atic	 review	and	meta‐analysis.	 Journal of Periodontology,	77,	 1635–
1642.	https	://doi.org/10.1902/jop.2006.050443
Joseph,	 P.,	 Leong,	 D.,	McKee,	M.,	 Anand,	 S.	 S.,	 Schwalm,	 J.‐D.,	 Teo,	
K.,	…	Yusuf,	S.	(2017).	Reducing	the	global	burden	of	cardiovascu‐
lar	disease.	Part	1:	The	epidemiology	and	risk	factors.	Circulatory 
Research,	 121(6),	 677–694.	 https	://doi.org/10.1161/CIRCR	
ESAHA.117.308903
Kapellas,	K.,	Maple‐Brown,	L.	 J.,	 Jamieson,	L.	M.,	Do,	L.	G.,	O'Dea,	K.,	
Brown,	 A.,	 …	 Skilton,	 M.	 R.	 (2014).	 Effect	 of	 periodontal	 therapy	
on	 arterial	 structure	 and	 function	 among	 aboriginal	 Australians:	 A	
randomized,	controlled	trial.	Hypertension,	64,	702–708.	https	://doi.
org/10.1161/HYPER	TENSI	ONAHA.114.03359	
Kassebaum,	N.	 J.,	 Bernabe,	 E.,	Dahiya,	M.,	Bhandari,	 B.,	Murray,	C.	 J.,	
&	 Marcenes,	 W.	 (2014).	 Global	 burden	 of	 severe	 periodontitis	 in	
1990–2010:	 A	 systematic	 review	 and	 meta‐regression.	 Journal of 






for	 the	global	burden	of	diseases,	 injuries,	and	risk	 factors.	Journal 
of Dental Research,	96(4),	 380–387.	 https	://doi.org/10.1177/00220	
34517	693566
Kaushal,	S.,	Singh,	A.	K.,	Lal,	N.,	Das,	S.	K.,	&	Mahdi,	A.	A.	(2019).	Effect	
of	 periodontal	 therapy	 on	 disease	 activity	 in	 patients	 of	 rheuma‐
toid	 arthritis	 with	 chronic	 periodontitis.	 Journal of Oral Biology 
and Craniofacial Research,	 9,	 128–132.	 https	://doi.org/10.1016/j.
jobcr.2019.02.002
Koh,	K.	K.,	 Son,	 J.	W.,	Ahn,	 J.	 Y.,	 Jin,	D.	K.,	 Kim,	H.	 S.,	 Choi,	 Y.	M.,	…	
Shin,	E.	K.	(2002).	Comparative	effects	of	diet	and	statin	on	NO	bio‐
activity	and	matrix	metalloproteinases	 in	hypercholesterolemic	pa‐
tients	with	coronary	artery	disease.	Arteriosclerosis, Thrombosis, and 
Vascular Biology,	22,	e19–23.	https	://doi.org/10.1161/01.ATV.00000	
30997.02059.BB
Koppolu,	P.,	Durvasula,	 S.,	 Palaparthy,	R.,	Rao,	M.,	 Sagar,	V.,	Reddy,	 S.	
K.,	 &	 Lingam,	 S.	 (2013).	 Estimate	 of	 CRP	 and	 TNF‐alpha	 level	 be‐
fore	 and	 after	 periodontal	 therapy	 in	 cardiovascular	 disease	 pa‐




sive	 Actinobacillus actinomycetemcomitans and Porphyromonas gin‐








Heart Journal,	 35,	 2383–2431.	 https	://doi.org/10.1093/eurhe	artj/
ehu282
Kwak,	 E.	 J.,	 Nam,	 S.,	 Park,	 K.	 M.,	 Kim,	 S.	 Y.,	 Huh,	 J.,	 &	 Park,	 W.	
(2019).	 Bleeding	 related	 to	 dental	 treatment	 in	 patients	 tak‐
ing	 novel	 oral	 anticoagulants	 (NOACs):	 A	 retrospective	 study.	




on	 direct	 oral	 anticoagulants:	 A	 retrospective	 controlled	 cohort	
     |  15SANZ et Al.




lation‐based	study	in	Taiwan.	Clinical Interventions in Aging,	10,	175–
182.	https	://doi.org/10.2147/CIA.S67854
Li,	C.,	Lv,	Z.,	Shi,	Z.,	Zhu,	Y.,	Wu,	Y.,	Li,	 L.,	&	 Iheozor‐Ejiofor,	Z.	 (2017).	
Periodontal	therapy	for	the	management	of	cardiovascular	disease	in	
patients	with	chronic	periodontitis.	Cochrane Database of Systematic 
Reviews,	11,	 CD009197.	 https	://doi.org/10.1002/14651	858.CD009	
197.pub3
Lillis,	 T.,	 Ziakas,	 A.,	 Koskinas,	 K.,	 Tsirlis,	 A.,	 &	 Giannoglou,	 G.	 (2011).	
Safety	of	dental	extractions	during	uninterrupted	single	or	dual	an‐
tiplatelet	 treatment.	American Journal of Cardiology,	108,	 964–967.	
https	://doi.org/10.1016/j.amjca	rd.2011.05.029
Linden,	G.	 J.,	Linden,	K.,	Yarnell,	 J.,	Evans,	A.,	Kee,	F.,	&	Patterson,	
C.	 C.	 (2012).	 All‐cause	 mortality	 and	 periodontitis	 in	 60–70‐
year‐old	 men:	 A	 prospective	 cohort	 study.	 Journal of Clinical 
Periodontology,	 39,	 940–946.	 https	://doi.org/10.1111/ 
j.1600‐051X.2012.01923.x
Linden,	G.	J.,	Lyons,	A.,	&	Scannapieco,	F.	A.	(2013).	Periodontal	systemic	







odontal	therapy.	Journal of Clinical Periodontology,	43,	652–658.	https	
://doi.org/10.1111/jcpe.12575	




Loos,	 B.	 G.,	 Papantonopoulos,	 G.,	 Jepsen,	 S.,	 &	 Laine,	 M.	 L.	 (2015).	
What	 is	 the	 Contribution	 of	 Genetics	 to	 Periodontal	 Risk?	Dental 
Clinics of North America,	 59,	 761–780.	 https	://doi.org/10.1016/j.
cden.2015.06.005
Lopez,	 N.	 J.,	 Quintero,	 A.,	 Casanova,	 P.	 A.,	 Ibieta,	 C.	 I.,	 Baelum,	 V.,	 &	
Lopez,	R.	(2012).	Effects	of	periodontal	therapy	on	systemic	markers	
of	 inflammation	 in	patients	with	metabolic	syndrome:	A	controlled	
clinical	 trial.	 Journal of Periodontology,	 83,	 267–278.	 https	://doi.
org/10.1902/jop.2011.110227
Lu,	 B.,	 Parker,	 D.,	 &	 Eaton,	 C.	 B.	 (2008).	 Relationship	 of	 periodon‐
tal	 attachment	 loss	 to	 peripheral	 vascular	 disease:	 An	 analysis	 of	
NHANES	 1999–2002	 data.	 Atherosclerosis,	 200,	 199–205.	 https	://
doi.org/10.1016/j.ather	oscle	rosis.2007.12.037
Luan,	Z.,	Chase,	A.	 J.,	&	Newby,	A.	C.	 (2003).	 Statins	 inhibit	 secretion	
of	metalloproteinases‐1,	 ‐2,	 ‐3,	 and	 ‐9	 from	 vascular	 smooth	mus‐
cle	cells	and	macrophages.	Arteriosclerosis, Thrombosis, and Vascular 
Biology,	23,	769–775.	https	://doi.org/10.1161/01.ATV.00000	68646. 
76823.AE
Madrid,	 C.,	 &	 Sanz,	 M.	 (2009).	 What	 influence	 do	 anticoagulants	
have	 on	 oral	 implant	 therapy?	 A	 systematic	 review.	 Clinical Oral 









in	 chronic	 periodontitis.	Clinical and Experimental Immunology,	147,	
255–264.	https	://doi.org/10.1111/j.1365‐2249.2006.03276.x
Matthews,	J.	B.,	Wright,	H.	J.,	Roberts,	A.,	Ling‐Mountford,	N.,	Cooper,	
P.	R.,	&	Chapple,	 I.	 L.	 (2007b).	Neutrophil	 hyper‐responsiveness	 in	
periodontitis.	 Journal of Dental Research,	 86,	 718–722.	 https	://doi.
org/10.1177/15440	59107	08600806
Meisel,	P.,	Kroemer,	H.	K.,	Nauck,	M.,	Holtfreter,	B.,	&	Kocher,	T.	(2014).	
Tooth	 loss,	 periodontitis,	 and	 statins	 in	 a	 population‐based	 fol‐
low‐up	 study.	 Journal of Periodontology,	 85,	 e160–168.	 https	://doi.
org/10.1902/jop.2013.130456
Mendez,	M.	V.,	Scott,	T.,	 LaMorte,	W.,	Vokonas,	P.,	Menzoian,	 J.	O.,	&	
Garcia,	R.	 (1998).	An	 association	between	periodontal	 disease	 and	
peripheral	 vascular	 disease.	American Journal of Surgery,	176,	 153–
157.	https	://doi.org/10.1016/S0002‐9610(98)00158‐5
Miclotte,	I.,	Vanhaverbeke,	M.,	Agbaje,	J.	O.,	Legrand,	P.,	Vanassche,	T.,	





dental	 treatment	 and	 risk	 for	 vascular	 events:	 A	 self‐controlled	






findings	of	3	months.	Journal of Clinical Periodontology,	46,	321–331.	
https	://doi.org/10.1111/jcpe.13085	




Muniz,	 F.,	 Taminski,	 K.,	 Cavagni,	 J.,	 Celeste,	 R.	 K.,	 Weidlich,	 P.,	 &	
Rosing,	 C.	 K.	 (2018).	 The	 effect	 of	 statins	 on	 periodontal	 treat‐
ment‐a	systematic	review	with	meta‐analyses	and	meta‐regression.	





risk	 locus.	 Scientific Reports,	 8,	 13678.	 https	://doi.org/10.1038/
s41598‐018‐31980‐8
Napenas,	 J.	 J.,	Hong,	C.	H.,	Brennan,	M.	T.,	 Furney,	 S.	 L.,	 Fox,	P.	C.,	
&	 Lockhart,	 P.	 B.	 (2009).	 The	 frequency	 of	 bleeding	 complica‐
tions	 after	 invasive	 dental	 treatment	 in	 patients	 receiving	 sin‐
gle	 and	 dual	 antiplatelet	 therapy.	 Journal of the American Dental 
Association,	 140,	 690–695.	 https	://doi.org/10.14219/	jada.archi	
ve.2009.0255
Nathwani,	 S.,	 &	Martin,	 K.	 (2016).	 Exodontia	 in	 dual	 antiplatelet	 ther‐
apy:	The	evidence.	British Dental Journal,	220,	235–238.	https	://doi.
org/10.1038/sj.bdj.2016.173
Nordendahl,	 E.,	 Kjellstrom,	 B.,	 Fored,	 C.	M.,	 Ekbom,	 A.,	 Svensson,	 T.,	
Norhammar,	A.,	&	Gustafsson,	A.	(2018).	Invasive	dental	treatment	
and	risk	for	a	first	myocardial	infarction.	Journal of Dental Research,	
97,	1100–1105.	https	://doi.org/10.1177/00220	34518	767834
O'Donnell,	 M.	 J.,	 Chin,	 S.	 L.,	 Rangarajan,	 S.,	 Xavier,	 D.,	 Liu,	 L.,	
Zhang,	 H.,	 …	 INTERSTROKE	 Investigators	 (2016).	 Global	 and	
regional	 effects	 of	 potentially	 modifiable	 risk	 factors	 associ‐
ated	with	acute	stroke	 in	32	countries	 (INTERSTROKE):	A	case‐




and	 Vascular	 Events	 (PAVE)	 Study:	 A	 pilot	 multicentered,	 ran‐
domized,	 controlled	 trial	 to	 study	 effects	 of	 periodontal	 ther‐
apy	 in	 a	 secondary	 prevention	 model	 of	 cardiovascular	 disease.	
16  |     SANZ et Al.
Journal of Periodontology,	 80,	 190–201.	 https	://doi.org/10.1902/
jop.2009.080007
Orlandi,	M.,	Graziani,	 F.,	 &	D’Aiuto,	 F.	 (2019)	 Periodontal	 therapy	 and	
cardiovascular	risk.	Periodontology 2000,	(in	press).
Paraskevas,	 S.,	 Huizinga,	 J.	 D.,	 &	 Loos,	 B.	 G.	 (2008).	 A	 systematic	 re‐
view	 and	 meta‐analyses	 on	 C‐reactive	 protein	 in	 relation	 to	 peri‐





European Heart Journal,	 40,	 1138–1145.	 https	://doi.org/10.1093/
eurhe	artj/ehy836
Patel,	J.	P.,	Woolcombe,	S.	A.,	Patel,	R.	K.,	Obisesan,	O.,	Roberts,	L.	N.,	












Perry,	 D.	 J.,	 Noakes,	 T.	 J.,	 Helliwell,	 P.	 S.,	 &	 British	 Dental,	 S.	 (2007).	







Quist‐Paulsen,	P.	 (2010).	 Statins	 and	 inflammation:	An	update.	Current 
Opinion in Cardiology,	 25,	 399–405.	 https	://doi.org/10.1097/
HCO.0b013	e3283	398e53
Rafferty,	 B.,	 Jönsson,	 D.,	 Kalachikov,	 S.,	 Demmer,	 R.	 T.,	 Nowygrod,	
R.,	 Elkind,	 M.	 S.,	 …	 Kozarov,	 E.	 (2011).	 Impact	 of	 monocytic	 cells	
on	 recovery	 of	 uncultivable	 bacteria	 from	 atherosclerotic	 le‐
sions.	 Journal of Internal Medicine,	 270,	 273–280.	 https	://doi.
org/10.1111/j.1365‐2796.2011.02373.x
Range,	H.,	Labreuche,	J.,	Louedec,	L.,	Rondeau,	P.,	Planesse,	C.,	Sebbag,	
U.,	 …	 Meilhac,	 O.	 (2014).	 Periodontal	 bacteria	 in	 human	 carotid	
atherothrombosis	 as	 a	 potential	 trigger	 for	 neutrophil	 activation.	
Atherosclerosis,	 236,	 448–455.	 https	://doi.org/10.1016/j.ather	oscle	
rosis.2014.07.034
Reichert,	 S.,	 Schulz,	 S.,	Benten,	A.	C.,	 Lutze,	A.,	 Seifert,	T.,	 Schlitt,	M.,	
…	 Schlitt,	 A.	 (2016).	 Periodontal	 conditions	 and	 incidence	 of	 new	
cardiovascular	 events	 among	 patients	 with	 coronary	 vascular	 dis‐











of	 global	 cardiovascular	mortality.	New England Journal of Medicine,	
372,	1333–1341.	https	://doi.org/10.1056/NEJMo	a1406656
Roth,	G.	A.,	Johnson,	C.,	Abajobir,	A.,	Abd‐Allah,	F.,	Abera,	S.	F.,	Abyu,	
G.,	 …	 Murray,	 C.	 (2017).	 Global,	 regional,	 and	 national	 burden	 of	
cardiovascular	diseases	for	10	causes,	1990	to	2015.	Journal of the 
American College of Cardiology,	70,	 1–25.	 https	://doi.org/10.1016/j.
jacc.2017.04.052
Saffi,	 M.	 A.	 L.,	 Rabelo‐Silva,	 E.	 R.,	 Polanczyk,	 C.	 A.,	 Furtado,	 M.	 V.,	
Montenegro,	M.	M.,	Ribeiro,	I.	W.	J.,	…	Haas,	A.	N.	(2018).	Periodontal	
therapy	and	endothelial	function	in	coronary	artery	disease:	A	ran‐
domized	 controlled	 trial.	Oral Diseases,	24,	 1349–1357.	 https	://doi.
org/10.1111/odi.12909	
Sakoda,	 K.,	 Yamamoto,	 M.,	 Negishi,	 Y.,	 Liao,	 J.	 K.,	 Node,	 K.,	 &	 Izumi,	
Y.	 (2006).	 Simvastatin	 decreases	 IL‐6	 and	 IL‐8	 production	 in	 epi‐
thelial	 cells.	 Journal of Dental Research,	 85,	 520–523.	 https	://doi.
org/10.1177/15440	59106	08500608
Sangwan,	A.,	Tewari,	S.,	Singh,	H.,	Sharma,	R.	K.,	&	Narula,	S.	C.	(2013).	
Periodontal	 status	 and	 hyperlipidemia:	 Statin	 users	 versus	 non‐
users.	 Journal of Periodontology,	84,	 3–12.	 https	://doi.org/10.1902/
jop.2012.110756
Sangwan,	A.,	Tewari,	S.,	Singh,	H.,	Sharma,	R.	K.,	&	Narula,	S.	C.	(2016).	
Effect	 of	 hyperlipidemia	 on	 response	 to	 nonsurgical	 periodontal	
therapy:	Statin	users	versus	nonusers.	European Journal of Dentistry,	
10,	69–76.	https	://doi.org/10.4103/1305‐7456.175685
Saver,	B.	G.,	Hujoel,	 P.	 P.,	Cunha‐Cruz,	 J.,	&	Maupome,	G.	 (2007).	Are	
statins	 associated	 with	 decreased	 tooth	 loss	 in	 chronic	 periodon‐
titis?	 Journal of Clinical Periodontology,	 34,	 214–219.	 https	://doi.
org/10.1111/j.1600‐051X.2006.01046.x
Saxlin,	 T.,	 Suominen‐Taipale,	 L.,	 Knuuttila,	 M.,	 Alha,	 P.,	 &	 Ylostalo,	
P.	 (2009).	 Dual	 effect	 of	 statin	 medication	 on	 the	 periodon‐










bacterial	infection.	Journal of Medical Genetics,	48,	38–47.	https	://doi.
org/10.1136/jmg.2010.078998
Schenkein,	H.	A.,	&	Loos,	B.	G.	(2013).	Inflammatory	mechanisms	linking	
periodontal	 diseases	 to	 cardiovascular	 diseases.	 Journal of Clinical 
Periodontology,	 40(Suppl	 14),	 S51–69.	 https	://doi.org/10.1111/
jcpe.12060 
Schenkein,	 H.	 A.,	 Papapanou,	 P.	 N.,	 Genco,	 R.,	 &	 Sanz,	 M.	 (2019)	
Mechanisms	underlying	the	association	betweem	periodontitis	and	
atherosclerotic	disease.	Periodontology 2000,	(in	press).





S.	 (2013).	 Periodontal	 disease	 and	 recurrent	 vascular	 events	 in	
stroke/transient	 ischemic	 attack	 patients.	 Journal of Stroke and 
Cerebrovascular Diseases,	22,	 1420–1427.	 https	://doi.org/10.1016/j.
jstro	kecer	ebrov	asdis.2013.06.024
Sharma,	 P.,	 Dietrich,	 T.,	 Ferro,	 C.	 J.,	 Cockwell,	 P.,	 &	 Chapple,	 I.	 L.	
(2016).	 Association	 between	 periodontitis	 and	 mortality	 in	 stages	
3–5	 chronic	 kidney	 disease:	 NHANES	 III	 and	 linked	 mortality	







Societies	 on	 Cardiovascular	 Disease	 Prevention	 inClinical	 Practice	
     |  17SANZ et Al.
(2016)	 European	 guidelines	 on	CVD	prevention	 in	 clinical	 practice	
2016. European Journal of Preventive Cardiology,	 23,	 NP1‐NP96.	 
https	://doi.org/10.1177/20474	87316	653709
Smeeth,	 L.,	 Thomas,	 S.	 L.,	 Hall,	 A.	 J.,	 Hubbard,	 R.,	 Farrington,	 P.,	 &	
Vallance,	 P.	 (2004).	 Risk	 of	 myocardial	 infarction	 and	 stroke	 after	
acute	infection	or	vaccination.	New England Journal of Medicine,	351,	
2611–2618.	https	://doi.org/10.1056/NEJMo	a041747
Steffel,	 J.,	 Verhamme,	 P.,	 Potpara,	 T.	 S.,	 Albaladejo,	 P.,	 Antz,	 M.,	
Desteghe,	 L.…	 ESC	 Scientific	Document	Group	 (2018a).	 The	 2018	
European	Heart	Rhythm	Association	Practical	Guide	on	the	use	of	
non‐vitamin	K	antagonist	oral	anticoagulants	 in	patients	with	atrial	
fibrillation:	 Executive	 summary.	 Europace,	 20,	 1231–1242.	 https	://
doi.org/10.1093/europ	ace/euy054
Steffel,	J.,	Verhamme,	P.,	Potpara,	T.	S.,	Albaladejo,	P.,	Antz,	M.,	Desteghe,	
L.…	 ESC	 Scientific	 Document	 Group	 (2018b).	 The	 2018	 European	
Heart	Rhythm	Association	Practical	Guide	on	the	use	of	non‐vitamin	
K	 antagonist	 oral	 anticoagulants	 in	 patients	with	 atrial	 fibrillation.	
European Heart Journal,	 39,	 1330–1393.	 https	://doi.org/10.1093/
eurhe	artj/ehy136
Subramanian,	 S.,	 Emami,	 H.,	 Vucic,	 E.,	 Singh,	 P.,	 Vijayakumar,	 J.,	 Fifer,	
K.	M.,	 …	 Tawakol,	 A.	 (2013).	 High‐dose	 atorvastatin	 reduces	 peri‐
odontal	 inflammation:	A	novel	pleiotropic	effect	of	 statins.	 Journal 











the	 in	vitro	effects	of	 statins	on	oral	 and	perioral	microorganisms.	




review/meta‐analysis.	Journal of Clinical Periodontology,	39,	213–228.	
https	://doi.org/10.1111/j.1600‐051X.2011.01784.x
Tonetti,	M.	S.,	Van	Dyke,	T.	E.	&	Working	group	1	of	the	Joint	EFP/AAP	
Workshop	 (2013).	 Periodontitis	 and	 atherosclerotic	 cardiovascu‐
lar	 disease:	 Consensus	 report	 of	 the	 Joint	 EFP/AAP	Workshop	 on	
Periodontitis	and	Systemic	Diseases.	Journal of Clinical Periodontology,	
40(Suppl	14),	S24–29.	https	://doi.org/10.1111/jcpe.12089	
U.S.	Senate	Committee	on	Health,	Education	Labor	&	Pensions	 (2011)	
The state of chronic disease prevention: Hearing before the Committee 
on Health, Education, Labor, and Pensions.
Valgimigli,	M.,	Bueno,	H.,	Byrne,	R.	A.,	Collet,	J.	P.,	Costa,	F.,	Jeppsson,	
A.…	 ESC	 Scientific	 Document	 Group	 (2018).	 2017	 ESC	 focused	
update	on	dual	 antiplatelet	 therapy	 in	 coronary	artery	disease	de‐
veloped	 in	 collaboration	 with	 EACTS.	 European Journal of Cardio‐
Thoracic Surgery,	53,	34–78.	https	://doi.org/10.1093/ejcts/	ezx334
Velsko,	I.	M.,	Chukkapalli,	S.	S.,	Rivera,	M.	F.,	Lee,	J.	Y.,	Chen,	H.,	Zheng,	
D.,	…	Kesavalu,	L.	 (2014).	Active	 invasion	of	oral	and	aortic	 tissues	
by Porphyromonas gingivalis	 in	mice	causally	 links	periodontitis	and	
atherosclerosis.	PLoS ONE,	9,	e97811.	https	://doi.org/10.1371/journ	
al.pone.0097811
Velsko,	 I.	M.,	Chukkapalli,	 S.	 S.,	Rivera‐Kweh,	M.	F.,	Zheng,	D.,	Aukhil,	
I.,	Lucas,	A.	R.,	…	Kesavalu,	L.	(2015).	Periodontal	pathogens	invade	
gingiva	 and	aortic	 adventitia	 and	elicit	 inflammasome	activation	 in	




hypertensive	patients:	A	pilot	study.	Journal of Clinical Periodontology,	
40,	681–687.	https	://doi.org/10.1111/jcpe.12110	
Viereck,	 V.,	 Grundker,	 C.,	 Blaschke,	 S.,	 Frosch,	 K.	 H.,	 Schoppet,	M.,	
Emons,	G.,	&	Hofbauer,	 L.	C.	 (2005).	Atorvastatin	 stimulates	 the	
production	 of	 osteoprotegerin	 by	 human	 osteoblasts.	 Journal of 
Cellular Biochemistry,	 96,	 1244–1253.	 https	://doi.org/10.1002/
jcb.20598	
Wilkins,	E.,	Wilson,	L.,	Wickramasinghe,	K.,	Bhatnagar,	P.,	Leal,	J.,	Luengo‐
Fernandez,	 R.,	 …	 Townsend,	 N.	 (2017).	 European Cardiovascular 
Disease Statistics 2017.	Brussels:	European	Heart	Network.
Wright,	 H.	 J.,	 Matthews,	 J.	 B.,	 Chapple,	 I.	 L.,	 Ling‐Mountford,	 N.,	 &	
Cooper,	P.	R.	(2008).	Periodontitis	associates	with	a	type	1	IFN	sig‐





British Medical Journal Open,	 7,	 e015952.	 https	://doi.org/10.1136/
bmjop	en‐2017‐015952
Yang,	 J.,	 Wu,	 J.,	 Liu,	 Y.,	 Huang,	 J.,	 Lu,	 Z.,	 Xie,	 L.,	 …	 Ji,	 Y.	 (2014).	
Porphyromonas gingivalis	 infection	 reduces	 regulatory	 T	 cells	 in	 in‐






between	 periodontitis	 and	 peripheral	 artery	 disease:	A	 systematic	
review	 and	 meta‐analysis.	 BMC Cardiovascular Disorders,	 18,	 141.	
https	://doi.org/10.1186/s12872‐018‐0879‐0
Yebyo,	H.	G.,	Aschmann,	H.	E.,	Kaufmann,	M.,	&	Puhan,	M.	A.	 (2019).	






Yang,	 J.	 Y.	 (2017).	 Effect	 of	 intensive	 periodontal	 therapy	 on	
blood	 pressure	 and	 endothelial	 microparticles	 in	 patients	 with	
prehypertension	and	periodontitis:	A	randomized	controlled	trial.	
Journal of Periodontology,	 88,	 711–722.	 https	://doi.org/10.1902/
jop.2017.160447
How to cite this article:	Sanz	M,	Marco	del	Castillo	A,	Jepsen	
S,	et	al.	Periodontitis	and	cardiovascular	diseases:	Consensus	
report.	J Clin Periodontol. 2019;00:1–21. https	://doi.
org/10.1111/jcpe.13189	Appendix	1
18  |     SANZ et Al.
ANTITHROMBOTIC THER APY: WHEN, HOW 
AND WHY. COMPREHENSIVE APPROACH 
FOR OR AL HE ALTH PROFESSIONAL S
Introduction
The	 use	 of	 antithrombotic	 therapy	 is	 one	 of	 the	 cornerstones	 of	





agents,	 indications	 and	 timing	 of	 these	 therapeutic	 interventions	
is	a	matter	of	constant	discussion	and	controversy.	This	document	
pretends	to	complement	the	current	recommendations	of	the	Joint	
Committee	 of	 the	 European	 Federation	 for	 Periodontology	 (EFP)	





Pharmacology of antithrombotic agents
Thrombus	prevention	is	based	on	the	interruption	of	the	haemosta‐
sis,	and	this	can	be	achieved	by	intervening	in	the	primary	haemosta‐
sis	 (namely,	 platelet	 function)	 or	 secondary	haemostasis	 (basically,	
humoral	factors).	Agents	whose	main	target	is	primary	haemostasis	
are	usually	called	antiplatelet	drugs	and	are	widely	used	in	circum‐
stances	 in	 which	 the	 main	 phenomenon	 is	 local	 thrombosis	 (e.g.	
myocardial	infarction,	non‐embolic	strokes,	etc.).	On	the	other	hand,	
drugs	that	alter	secondary	haemostasis	are	generally	referred	to	as	




































20	 years.	 Their	 use	 is	widely	 extended,	 as	 they	 are	 very	 cheap	
agents	and	 the	medical	community	 is	very	comfortable	with	 its	
use.	Another	positive	feature	 is	that	the	dose	can	be	titrated	to	




monthly	 to	 adjust	 the	 dosage	 regime.	 In	 addition,	 these	 agents	
are	tightly	bound	to	plasmatic	proteins	and	tend	to	interact	with	
medications	that	displace	them	from	that	union	(e.g.	non‐steroi‐

















more	 infrequent.	Regarding	outcomes,	 these	drugs	have	 shown	
to	be	at	least	non‐inferior	to	acenocumarol	in	embolic	prevention	
with	a	better	safety	profile	as	measured	by	a	lower	bleeding	risk.	
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This	better	overall	profile	is	the	reason	why	DOACs	are	now	the	
first	line	therapy	with	patients	with	atrial	fibrillation	(AF)	accord‐













medications	 are	 normally	 used	 during	 short	 periods	 of	 time	while	
bridging	in	between	drugs.
Indications
















For double antiplatelet therapy (DAPT)
•	 Coronary	artery	disease	(CAD):	patients	with	CAD	require	DAPT	
in	 the	 following	 situations	 (Ibanez	 et	 al.,	 2014;	Neumann	 et	 al.,	
2008):
o	 Chronic	 angina	 pectoris:	 after	 the	 implantation	 of	 a	 coro‐






o	 Acute	 coronary	 syndrome	 (myocardial	 infarction):	 after	 a	









•	 Cerebrovascular	 disease	 (CeVD):	 patients	 with	 CeVD	 require	
DAPT	in	the	following	situations:
o	 Chronic	carotid	disease:	in	symptomatic	patients	with	carotid	

















tent	positive	results	 in	this	scenario.	Thus,	 it	 is	not	routinely	
recommended.
Chronic Oral Anticoagulation (COA)
There	are	three	main	indications	for	anticoagulation:
•	 Deep	 vein	 thrombosis	 (DVT)	 and	 pulmonary	 embolism	 (PE)	
(Konstantinides	 et	 al.,	 2019):	 both	VKA	 and	DOACs	 are	 autho‐
rized	for	this	indication.	The	duration	of	the	therapy	depends	on	
whether	it	is	assumed	to	be	a	spontaneous	case	(3–6	months)	or	




Flutter):	 the	 indication	 for	 chronic	 anticoagulation	 in	 the	 set‐
ting	of	AF/AFlutter	 is	guided	by	 the	 risk	of	embolism.	Although	
the	method	 for	 the	 risk	 estimation	 varies	worldwide,	 European	
Society	 of	 Cardiology	 (ESC)	 guidelines	 recommend	 the	 use	 of	
CHADSVASc	 scale.	 Generally,	 it	 is	 accepted	 that	 the	 following	
patients	with	a	score	equal	to	2	or	higher	must	use	chronic	oral	




uation	 includes	 significant	mitral	 stenosis	 and	mechanical	 valve	
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prosthesis.	Tissue	valves	are	not	at	a	high	risk	of	systemic	embo‐
















for	DAPT	and	COA	 is	normally	 seen	 in	patients	 that	are	undergo‐
ing	coronary	 stent	 implantation	and	have	either	atrial	 arrhythmias	
(more	frequent)	or	mitral	stenosis/mechanical	valves	(less	frequent).	









Treatment withdrawal: safety and rationale
It	is	not	the	purpose	of	this	paper	to	give	recommendations	on	tim‐
ing	and	 indications	of	withdrawal,	but	 rather	explain	 the	changes/
effects	that	the	antithrombotic	withdrawal	entails.
Risks of antiplatelet withdrawal
The	 main	 risk	 of	 SAPT	 withdrawal	 is,	 of	 course,	 the	 increase	 in	
thrombotic	risk	as	explained	by	a	higher	chance	of	MI,	stroke	or	pe‐
ripheral	artery	 thrombosis.	 It	 should	be	noticed	 that	patients	with	
implanted	 stents	 are	 at	 a	much	 greater	 risk	 of	 acute	 events	 after	
SAPT	withdrawal.
Regarding	DAPT,	the	crucial	thing	to	be	understood	is	that	when‐
ever	DAPT	 is	 used,	 an	 abnormally	 high	 thrombotic	 risk	 underlies.	
The	duration	of	DAPT	regimes	depends	on	several	factors,	but	there	
should	be	always	a	preestablished	goal	 (e.g.	6	months,	12	months,	
etc.).	 Transitioning	 from	DAPT	 to	 SAPT	before	 the	preestablished	
goal	 should	 always	 be	 performed	 under	 cardiological	 supervision.	

















In	 patients	with	mitral	 stenosis	 or	mechanical	 heart	 valves,	 the	
discontinuation	of	VKA	leads	to	an	extremely	thrombotic	risk,	spe‐








anymore	 for	 procedures	 other	 that	 those	with	 high	 bleeding	 risk.	
After	an	oral	cavity	 intervention	with	significant	bleeding,	DOACs	
can	be	safely	restarted	24	hours	later.
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